JP2020114218A5 - - Google Patents

Download PDF

Info

Publication number
JP2020114218A5
JP2020114218A5 JP2020040540A JP2020040540A JP2020114218A5 JP 2020114218 A5 JP2020114218 A5 JP 2020114218A5 JP 2020040540 A JP2020040540 A JP 2020040540A JP 2020040540 A JP2020040540 A JP 2020040540A JP 2020114218 A5 JP2020114218 A5 JP 2020114218A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
composition according
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020040540A
Other languages
English (en)
Japanese (ja)
Other versions
JP6937858B2 (ja
JP2020114218A (ja
Filing date
Publication date
Priority claimed from JP2018042020A external-priority patent/JP2018113974A/ja
Application filed filed Critical
Publication of JP2020114218A publication Critical patent/JP2020114218A/ja
Publication of JP2020114218A5 publication Critical patent/JP2020114218A5/ja
Priority to JP2021111033A priority Critical patent/JP7250852B2/ja
Application granted granted Critical
Publication of JP6937858B2 publication Critical patent/JP6937858B2/ja
Priority to JP2022196712A priority patent/JP2023029993A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020040540A 2012-12-05 2020-03-10 Epoを標的とする抗体のための組成物および方法 Active JP6937858B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021111033A JP7250852B2 (ja) 2012-12-05 2021-07-02 Epoを標的とする抗体のための組成物および方法
JP2022196712A JP2023029993A (ja) 2012-12-05 2022-12-09 Epoを標的とする抗体のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261733566P 2012-12-05 2012-12-05
US61/733,566 2012-12-05
JP2018042020A JP2018113974A (ja) 2012-12-05 2018-03-08 Epoを標的とする抗体のための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018042020A Division JP2018113974A (ja) 2012-12-05 2018-03-08 Epoを標的とする抗体のための組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021111033A Division JP7250852B2 (ja) 2012-12-05 2021-07-02 Epoを標的とする抗体のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2020114218A JP2020114218A (ja) 2020-07-30
JP2020114218A5 true JP2020114218A5 (cg-RX-API-DMAC7.html) 2021-01-14
JP6937858B2 JP6937858B2 (ja) 2021-09-22

Family

ID=49881001

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015546561A Active JP6306605B2 (ja) 2012-12-05 2013-12-03 Epoを標的とする抗体のための組成物および方法
JP2018042020A Withdrawn JP2018113974A (ja) 2012-12-05 2018-03-08 Epoを標的とする抗体のための組成物および方法
JP2020040540A Active JP6937858B2 (ja) 2012-12-05 2020-03-10 Epoを標的とする抗体のための組成物および方法
JP2021111033A Active JP7250852B2 (ja) 2012-12-05 2021-07-02 Epoを標的とする抗体のための組成物および方法
JP2022196712A Pending JP2023029993A (ja) 2012-12-05 2022-12-09 Epoを標的とする抗体のための組成物および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2015546561A Active JP6306605B2 (ja) 2012-12-05 2013-12-03 Epoを標的とする抗体のための組成物および方法
JP2018042020A Withdrawn JP2018113974A (ja) 2012-12-05 2018-03-08 Epoを標的とする抗体のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021111033A Active JP7250852B2 (ja) 2012-12-05 2021-07-02 Epoを標的とする抗体のための組成物および方法
JP2022196712A Pending JP2023029993A (ja) 2012-12-05 2022-12-09 Epoを標的とする抗体のための組成物および方法

Country Status (29)

Country Link
US (5) US9365646B2 (cg-RX-API-DMAC7.html)
EP (2) EP2928921B1 (cg-RX-API-DMAC7.html)
JP (5) JP6306605B2 (cg-RX-API-DMAC7.html)
KR (2) KR102386154B1 (cg-RX-API-DMAC7.html)
CN (2) CN104968678B (cg-RX-API-DMAC7.html)
AP (1) AP2015008365A0 (cg-RX-API-DMAC7.html)
AR (1) AR093803A1 (cg-RX-API-DMAC7.html)
AU (4) AU2013355414B2 (cg-RX-API-DMAC7.html)
CA (1) CA2893767C (cg-RX-API-DMAC7.html)
CL (1) CL2015001472A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124028T1 (cg-RX-API-DMAC7.html)
DK (1) DK2928921T3 (cg-RX-API-DMAC7.html)
EA (1) EA033643B1 (cg-RX-API-DMAC7.html)
ES (1) ES2864326T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210517T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053669T2 (cg-RX-API-DMAC7.html)
LT (1) LT2928921T (cg-RX-API-DMAC7.html)
MX (1) MX368067B (cg-RX-API-DMAC7.html)
PH (1) PH12015501243B1 (cg-RX-API-DMAC7.html)
PL (1) PL2928921T3 (cg-RX-API-DMAC7.html)
PT (1) PT2928921T (cg-RX-API-DMAC7.html)
RS (1) RS61648B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201503567SA (cg-RX-API-DMAC7.html)
SI (1) SI2928921T1 (cg-RX-API-DMAC7.html)
TN (1) TN2015000124A1 (cg-RX-API-DMAC7.html)
TW (1) TW201434858A (cg-RX-API-DMAC7.html)
UY (1) UY35168A (cg-RX-API-DMAC7.html)
WO (1) WO2014089111A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201502291B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104968678B (zh) * 2012-12-05 2018-12-11 诺华股份有限公司 靶向epo的抗体的组合物和方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN104877971B (zh) * 2015-06-02 2018-03-30 汉恒生物科技(上海)有限公司 一种可以缓解小鼠心衰症状的携带mg53基因的腺相关病毒载体
EP3334842B1 (en) 2015-08-12 2022-03-02 Novartis AG Methods of treating ophthalmic disorders
US20190023806A1 (en) * 2015-10-21 2019-01-24 Qoolabs, Inc. Camelid hemoglobin antibodies and methods of use
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
ES2843974T3 (es) * 2016-03-17 2021-07-21 Tillotts Pharma Ag Anticuerpos anti-TNF alfa y fragmentos funcionales de los mismos
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018155997A1 (ko) 2017-02-27 2018-08-30 재단법인 대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
KR102167641B1 (ko) * 2018-08-27 2020-10-19 주식회사 사이루스 에리스로포이에틴 유래 펩티드를 함유하는 세포증식 촉진용 조성물
EP3863677A4 (en) * 2018-10-10 2022-12-28 The Johns Hopkins University POLY (Beta-AMINO ESTER) NANOPARTICLES FOR NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINA GENE THERAPY
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3222336A1 (en) * 2021-06-11 2022-12-15 Colyn MUNN System and method for detecting and classifying retinal microaneurysms
WO2023280391A1 (en) * 2021-07-06 2023-01-12 Andremacon S.R.L. Anti-erythropoietin antibody
JP7452516B2 (ja) 2021-10-28 2024-03-19 トヨタ自動車株式会社 注意能力検査装置、および、車両

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
HUT76369A (en) 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ATE394492T1 (de) 1996-10-28 2008-05-15 Univ Lausanne Verfahren zur oligomerisation von peptiden
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1998056906A1 (en) 1997-06-11 1998-12-17 Thoegersen Hans Christian Trimerising module
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
DE60136656D1 (de) 2000-12-05 2009-01-02 Alexion Pharma Inc Rationell entworfene Antikörper
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004089282A2 (en) 2002-08-09 2004-10-21 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
JP2006516192A (ja) 2002-10-18 2006-06-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP2990053A1 (en) 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20050255112A1 (en) 2004-05-17 2005-11-17 Lee Jong Y Compositions and methods for preventing erythropoietin-associated hypertension
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
ATE439123T1 (de) 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
EP1966237A2 (en) 2005-11-24 2008-09-10 Laboratoires Serono SA Erythropoietin polypeptides and uses thereof
TW200808822A (en) 2006-04-14 2008-02-16 Amgen Inc Erythropoietin receptor agonists
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
WO2008079877A2 (en) 2006-12-22 2008-07-03 Xenon Pharmaceuticals Inc. Compositions and methods for the diagnosis and treatment of iron-related disorders
WO2008112703A2 (en) 2007-03-12 2008-09-18 University Of Utah Research Foundation Compositions and methods for diagnosing and treating diabetic micro vascular complications
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
EP2072527A1 (en) 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
EP2803675A3 (en) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
HUE026179T2 (en) * 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
EP2321350A1 (en) 2008-08-28 2011-05-18 F. Hoffmann-La Roche AG Antibodies against human epo receptor
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
WO2010056893A1 (en) 2008-11-13 2010-05-20 Imclone Llc Humanization and affinity-optimization of antibodies
CA2965031C (en) 2009-01-15 2018-12-04 F. Hoffmann-La Roche Ag Antibodies against phosphorylated tyrosines on erythropoietin receptor (epor)
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2625203A1 (en) * 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
BR112013032235A2 (pt) 2011-06-15 2016-11-22 Hoffmann La Roche anticorpos do receptor de epo anti-humano e métodos de uso
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
EP2847219A1 (en) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin antibodies
WO2014035693A2 (en) 2012-08-31 2014-03-06 The Scripps Research Institute Methods and compositions related to modulators of eukaryotic cells
CN104968678B (zh) 2012-12-05 2018-12-11 诺华股份有限公司 靶向epo的抗体的组合物和方法

Similar Documents

Publication Publication Date Title
JP2020114218A5 (cg-RX-API-DMAC7.html)
US12404336B2 (en) Bispecific antagonist comprising a LAG-3 binding domain
JP6923602B2 (ja) 抗アクチビンa抗体及びその使用
JP2017536414A5 (cg-RX-API-DMAC7.html)
US10851157B2 (en) Antagonists targeting the TGF-β pathway
JP2018510617A5 (cg-RX-API-DMAC7.html)
HRP20210393T1 (hr) Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja
JP2016504416A5 (cg-RX-API-DMAC7.html)
JP2014523739A (ja) 抗angptl3抗体及びその使用
JP2018529764A (ja) 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
JP2024024114A5 (cg-RX-API-DMAC7.html)
WO2019195313A1 (en) Anti-vegf antagonist and pedf agonist constructs and uses thereof
JP2018527327A5 (cg-RX-API-DMAC7.html)
CN106565840A (zh) 抗乙肝表面抗原的抗体及其用途
JP2011503094A5 (cg-RX-API-DMAC7.html)
JPWO2020180819A5 (cg-RX-API-DMAC7.html)
JP2018523673A5 (cg-RX-API-DMAC7.html)
JPWO2019164219A5 (cg-RX-API-DMAC7.html)
JP2025525442A (ja) Ang2/vegf抗体およびその使用
JP2025519612A (ja) Igf1r抗体
JPWO2022013787A5 (cg-RX-API-DMAC7.html)
TW202530256A (zh) 多特異性抗原結合多肽之組合物及使用方法
JPWO2023132547A5 (cg-RX-API-DMAC7.html)
JP2025186267A (ja) 変異したTGFβ1-RII細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト
RU2021125763A (ru) Биспецифическое антитело, специфически связывающееся с vegf и ang2